When solving dyspareunia is not enough to restore sexual function in women with deep infiltrating endometriosis treated with dienogest.

OBJECTIVE: The aim of the study was evaluated dyspareunia and sexual function (SF) in women with deep endometriosis treated with Dienogest for 12 months.

METHODS: Prospective cohort study set in University of Campinas, Brazil, including thirty women with sonographic diagnosis of deep endometriosis and sexual dysfunction treated with 2░mg/daily Dienogest for 12 months. SF parameters were assessed by Female Sexual Function Index (FSFI) before and after the treatment and dyspareunia was quantified through Visual Analogic Scale(VAS) during the follow ups performed every 3 months. Statistical analysis was performed by ANOVA test as well as Statistical Analysis System version 9.4.

RESULTS: Women were on average 36.13 ± 6.24 years old and all of them showed sexual dysfunction (FSFI = 17.6 ± 5.7) before Dienogest; 88.3% had dyspareunia as main symptom related to deep endometriosis (VAS before 5,3±3,1). At the end of the treatment, dyspareunia showed a decrease of intensity (VAS after 3.7±3.3; p = 0.0093) and an improvement on FSFI index was accomplished (p = 0.0023) however, it did not restore SF completely, considering FSFI cut-off <26.55.

CONCLUSION: Long-term treatment for DIE with Dienogest has provided a decreasing in dyspareunia and also an enhancement on SF, although SF has not been restored to normal levels.